Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00052147" target="_blank" >RIV/00216224:14110/11:00052147 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/11:11276 RIV/65269705:_____/11:#0001311 RIV/00064190:_____/11:#0000235 RIV/00064165:_____/11:11276 RIV/00064173:_____/11:#0000382
Result on the web
<a href="http://dx.doi.org/10.1007/s00277-011-1206-3" target="_blank" >http://dx.doi.org/10.1007/s00277-011-1206-3</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00277-011-1206-3" target="_blank" >10.1007/s00277-011-1206-3</a>
Alternative languages
Result language
angličtina
Original language name
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma
Original language description
Many regimens containing novel drugs have been developed for multiple myeloma (MM). It is not yet clear whether some of the novel agents are better than others. In a retrospective study, we have analyzed the outcomes of patients with first relapse of MMtreated with thalidomide-based (T) regimens (n=105) or bortezomib-based (B) regimens (n=106). Both T and B groups were comparable regarding basic clinical parameters and first-line therapies. Combination of thalidomide with an alkylating drug (A) and dexamethasone (D) was used in 91 cases, T with D in five cases, and T alone in nine cases. A combination of bortezomib with A and D was used in 58 patients, B with D or A in 40 patients, and B alone in eight patients. In the T group, ORR was 51%, median TTPfrom the start of treatment for relapse of 13.1 months, and median OS of 30.4 months. In the B group, ORR was 50% with median TTP of 16.7 months and median OS of 37.2 months. No significant differences in ORR (p=0.774), TTP (p=0.207), or
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Annals of hematology
ISSN
0939-5555
e-ISSN
—
Volume of the periodical
90
Issue of the periodical within the volume
12
Country of publishing house
DE - GERMANY
Number of pages
7
Pages from-to
1441-1447
UT code for WoS article
000296730700008
EID of the result in the Scopus database
—